Funding sources for the study: St. Paul's Hospital Foundation, Vancouver, BC, Canada (01866152).
The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis
Article first published online: 21 JAN 2014
© 2014 ARS-AAOA, LLC
International Forum of Allergy & Rhinology
Volume 4, Issue 5, pages 397–402, May 2014
How to Cite
How to Cite this Article: The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol. 2014;4:397–402., , , et al.
Potential conflict of interest: None provided.
Public clinical trial registration: http://clinicaltrials.gov/show/NCT01405339. The Effect of Budesonide Spray Via Mucosal Atomization Device on the Hypothalamic-Pituitary Axis: Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray.
- Issue published online: 25 APR 2014
- Article first published online: 21 JAN 2014
- Manuscript Accepted: 3 DEC 2013
- Manuscript Revised: 22 NOV 2013
- Manuscript Received: 13 AUG 2013
- St. Paul's Hospital Foundation, Vancouver, BC, Canada. Grant Number: 01866152
- chronic rhinosinusitis;
- mucosal atomization device;
- quality of life
Budesonide is a potent corticosteroid commonly prescribed for management of inflammation in chronic rhinosinusitis (CRS). The standard for prescribing budesonide is via impregnated nasal saline irrigation (INSI), although recently the mucosal atomization device (MAD) has emerged as a theoretically superior method of distributing medication into the sinuses. The MAD atomizes medication into small droplets and this is thought to enhance absorption and improve bioavailability. However, no studies have shown whether enhanced absorption and improved bioavailability of budesonide via MAD causes adrenal suppression. The objective of this study is to determine whether budesonide via MAD affects the hypothalamic-pituitary-adrenal (HPA) axis.
Twenty CRS patients were recruited from a tertiary rhinology clinic and randomized to take budesonide (1 mg) via MAD or via INSI twice a day for 60 days. The adrenocorticotropic hormone (ACTH) stimulation test and 22-item Sinonasal Outcomes Test (SNOT-22) questionnaire were administered on days 1, 30, and 60 of the study. Plasma budesonide and cortisol levels were simultaneously quantified using a high-performance liquid chromatography–tandem mass spectrometry technique.
There was no indication of adrenal suppression in either group (n = 20) based on ACTH stimulation test results nor was there significant plasma budesonide levels detected in either group. Quality of life, as indicated by SNOT-22, did not differ between groups at 60 days (p = 0.404; 95% confidence interval [CI], −37.2 to 15.9), but SNOT-22 scores for patients using MAD did show statistically significant improvement at 60 days compared to baseline (p = 0.02).
The MAD is likely a safe and effective method of delivering budesonide to the sinuses in the short term.